Antifungal Susceptibility of 3,4-di-hydropyrimidine-1-(H2)-L-H1-pyrrole Derivatives in Candida Clinical Isolates

Background and purpose: There is an increasing rate of drug resistance to azole among Candida species, so, finding new compounds that are effective in laboratory conditions, such as 3,4-dihydropyrimidine derivatives are important. The purpose of this study was to evaluate the antifungal sensitivity of 3,4-di-hydropyrimidine-1- (H2) -L- H1-pyrrole derivatives in Candida isolates. Materials and methods: Antifungal sensitivity of 102 Candida isolates with the origin of otomycosis to dihydropyrimidine derivatives and itraconazole were evaluated by broth microdilution according to CLSI-M27S4 guidelines. The serial dilution range of compounds and antifungal drug was 0.016-16 μg/ml. A concentration of compounds that showed at least 50% growth inhibition compared to the positive control group was considered as the minimum inhibitory concentration (MIC). Statistical analysis was performed in SPSS V16.  Results: Findings showed that 3,4-di-hydropyrimidine-1-(H2)-L-H1-pyrrole derivatives have higher MIC than itraconazole against Candida species. Also, comparing the MIC values of 3,4-di- hydropyrimidine with each other (P1-P4), P1 derivatives were found with lower MIC values than the other three derivatives and almost all compounds showed more efficacy against Candida albicans than other Candida species. Conclusion: Although the antifungal effects of 3,4-dihydropyrimidine-1-(H2)-L-H1-pyrrole derivatives against Candida species were lower than itraconazole, but, making structural changes in these compounds can increase their antifungal effects.